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ABSTRACT 
Non-syndromic cleft lip with or without cleft palate (NSCL/P) is a prevalent, complex 
congenital malformation. Genome-wide association studies (GWAS) on NSCL/P have 
consistently identified association for the 1p22 region, in which ARHGAP29 has emerged as 
the main candidate gene. ARHGAP29 re-sequencing studies in NSCL/P patients have 
identified rare variants; however their clinical impact is still unclear. In this study we 
identified ten rare variants in ARHGAP29, including five missense, one in-frame deletion, and 
four loss-of-function (LoF) variants, in a cohort of 188 familial NSCL/P cases. A significant 
mutational burden was found for LoF (Sequence Kernel Association Test, P=0.0005) but not 
for missense variants in ARHGAP29, suggesting that only LoF variants contribute to the 
etiology of NSCL/P. Penetrance was estimated as 59%, indicating that heterozygous LoF 
variants in ARHGAP29 confer a moderate risk to NSCL/P. The GWAS hits in IRF6 
(rs642961) and 1p22 (rs560426 and rs4147811) do not seem to contribute to the penetrance of 
the phenotype, based on co-segregation analysis.  Our data demonstrate that rare variants 
leading to haploinsufficiency of ARHGAP29 represent an important etiological clefting 
mechanism, and genetic testing for this gene might be taken into consideration in genetic 
counseling of familial cases.  
 
Keywords: Cleft lip and palate, GWAS, haploinsufficiency, IRF6, nonsense mutations, 
penetrance, rare variants, 1p22.   
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INTRODUCTION 
Non-syndromic cleft lip with or without cleft palate (NSCL/P) represents one of the most 
common congenital human malformations, affecting about one in 700 live born children 
worldwide, varying according to ethnicity and socioeconomic status. Both genetic and 
environmental factors contribute to the etiology of NSCL/P, and most cases fit a 
multifactorial pattern of inheritance 1,2. 
Genome-wide association studies (GWAS) have successfully detected several common 
susceptibility alleles for NSCL/P 3–8. The 1p22.1 region ranks among the most frequently 
replicated GWAS hits, originally implicating the gene ABCA4 5. However, this gene was 
largely excluded through its primarily retinal expression and known role in retinal disorders 9. 
Single Nucleotide Variants (SNVs) in the 1p22.1 region have also been suggested to affect a 
cis-enhancer of ARHGAP29 10. ARHGAP29 (Online Mendelian Inheritance in Man - OMIM: 
610496) is specifically expressed in the frontonasal and lateral prominences as well as the 
palatal shelves of murine embryos, which further reinforces it as a strong candidate 
underlying NSCL/P in the 1p22.1 region 11. About eighteen possibly pathogenic rare variants 
(eleven missense and seven loss-of-function) in ARHGAP29 have been reported in NSCL/P 
patients of European, Asian and African ancestries 11–14. However, it is not clear if both 
missense and loss-of-function (LoF) variants contribute to the phenotype. In order to address 
this issue, a systematic analysis of ARHGAP29 was conducted in a large cohort of 188 
familial NSCL/P cases. We have also investigated if previously identified GWAS hits at 
1p22.1 and in IRF6 contribute to the penetrance of the phenotype in individuals with 
pathogenic variants in ARHGAP29.  
 4 
 
 
SUBJECTS AND METHODS 
Ethical Compliance 
This study was approved by the Ethics Committee of the Instituto de Biociências 
(Universidade de São Paulo, Brazil) (CAAE: 37287314.6.0000.5464) and Great Ormond 
Street Hospital for Children NHS Trust Ethics Committee (REC No. 08H0713/46). Biological 
samples were obtained after signed informed consent by the patients, parents or legal 
guardians.  
 
Samples 
The NSCL/P cohort included 173 families from Brazil and fifteen families from the United 
Kingdom. The average number of affected individuals per family was 2.6 (ranging between 
two and seven), with coefficients of relationship (r) between ½ and 1/32.  ARHGAP29 
sequences were screened for rare variants in 188 probands and sixteen relatives (four affected 
and twelve non-affected), which were included for segregation analysis. Brazilian individuals 
were ascertained at the Hospital das Clínicas of Universidade de São Paulo (São Paulo, 
Brazil), Hospital de Clínicas de Porto Alegre (Rio Grande do Sul, Brazil) or during missions 
of Operation Smile Brazil, in the Brazilian states of Ceará, Alagoas, Pará, Rondônia and Rio 
de Janeiro. British individuals were ascertained at Great Ormond Street Hospital for Children 
(London, United Kingdom).  
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DNA samples were extracted either from whole blood (following standard protocols) or saliva 
(collected with Oragene® DNA Collection Kits OG-500 and OG-575, and purified following 
prepIT-L2P manufacturer’s instructions; DNA Genotek Inc., Ottawa, Canada). For controls, 
we used in-house whole exome sequencing data from 609 Brazilian and 601 British controls 
as well as public databases (1000 Genomes Project 15, Exome Variant Server/NHLBI ESP 
exomes 16, and Exome Aggregation Consortium – ExAC 17).  
 
ARHGAP29 variant screening 
ARHGAP29 coding regions and exon-intron boundaries were sequenced using next-
generation sequencing (NGS): twenty seven whole exome sequences from fifteen independent 
UK families (fifteen probands, three affected cousins and nine unaffected relatives), and 173 
targeted gene sequences from unrelated probands from the Brazilian cohort were included in 
the analysis. Sanger sequencing was used for one affected and three non-affected relatives 
from the Brazilian cohort. 
ARHGAP29 targeted sequencing was performed with Illumina MiSeq (Illumina, San Diego, 
CA, USA) sequencer, using Illumina’s Nextera kits for library preparation. KAPA Library 
Quantification kit (KAPA Biosystems) was used to quantify the libraries by real-time 
quantitative PCR. Whole-exome sequencing of the British samples was conducted using 
Agilent Exome v4 51Mb Capture Technology and enriched libraries were sequenced on an 
Illumina HiSeq2000 (Illumina). Sequence alignment, data processing, variant calling, and 
variant annotation were performed with Burrows-Wheeler Aligner (BWA; http://bio-
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bwa.sourceforge.net), Picard (http://broadinstitute.github.io/picard/), Genome Analysis 
Toolkit package (GATK; https://www.broadinstitute.org/gatk/) and ANNOVAR 
(http://www.openbioinformatics.org/annovar/), respectively. 
We considered as rare variants those with a frequency below 0.5% in public databases 
(ExAC, Exome Variant Server, and 1000 Genomes) and in our in-house control databases. 
Missense variants were considered as possibly pathogenic only if predicted to be 
possibly/probably damaging in at least three out of four in silico tools (Polyphen HumDiv and 
HumVar 18, SIFT 19, Mutation Taster 20 and LRT 21). Synonymous and UTR variants were 
excluded due to the uncertainty of their functional relevance. Splice site predictions were 
performed with Human Splicing Finder 3.0 22. 
All ARHGAP29 rare variants detected by NGS were visually inspected using the Integrative 
Genomics Viewer software (Broad Institute of MIT and Harvard). Indels and low coverage 
(<50x) variants were subsequently validated by Sanger sequencing.  
PCR primers for Sanger sequencing are described by Leslie et al. 12. Capillary electrophoresis 
was performed on an ABI3730 DNA Analyzer (Applied Biosystems, USA) and sequences 
were visualized using Sequencher® 5.2 sequence analysis software (Gene Codes, USA). The 
genomic position of variants are based on the hg19/GRCH37 version of the human reference 
genome (Genome Reference Consortium - 
http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/), and cDNA positions refer to 
the sequence NM_004815.3 (NCBI Reference Sequence Database - 
http://www.ncbi.nlm.nih.gov/refseq/). Pathogenic variants were submitted to the ClinVar 
public database (http://www.ncbi.nlm.nih.gov/clinvar/). 
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Genotyping of GWAS hits 
Genotypes for rs560426 (1p22), rs4147811 (1p22), and rs642961 (1q32) were obtained with 
the Illumina GoldenGate VeraCode assay, on Illumina BeadXpress platform, following 
manufacturer´s instructions, or by Sanger sequencing. Primers and PCR amplification 
conditions are available on request.  
 
Statistical analyses 
A gene-based Sequence Kernel Association Test (SKAT) was used to investigate the overall 
burden of ARHGAP29 rare variants among patients in comparison to 1210 Brazilian and 
British controls. Two-tailed Fisher’s exact test was performed to compare the proportion of 
patients and controls carrying rare variants in ARHGAP29. For these tests, rare variants were 
included after adjusting the sequence windows covered in all patients. Statistical significance 
was considered as P≤0.05. Penetrance was estimated using the PenCalc program 23. 
 
RESULTS 
Sequencing analysis of coding regions and exon-intron boundaries of ARHGAP29 in 188 
unrelated affected probands from familial cases of NSCL/P, led to the identification of ten 
rare variants. Five out of these ten were missense changes already described in public 
databases. The remaining five were unique variants, four of which were predicted to be LoF 
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and one was an in-frame deletion (Table 1). Among the missense variants, only c.91C>T 
(p.(L31F)) was predicted to be possibly pathogenic by three out of four in silico programs. 
However, segregation analysis in family BC84 excluded a likely causal role since the 
missense variant was absent in another affected relative. The non-frameshift deletion 
c.3326_3328delCAA (p.(T1109del)) was predicted to be non-pathogenic by two out of four in 
silico tools, so it was also not considered further.  
The four LoF variants, including three splice site and one stopgain variant, were all predicted 
to disrupt the protein, based on in silico analysis: the splice site variants were predicted to 
alter canonical donor (c.2109+1G>A, intron 18 and c.1576+1G>A, intron 14) or acceptor 
sites (c.698-1G>C, intron 7), according to the HSF tool; meanwhile, the variant c.1475C>A 
was predicted to cause premature termination of protein synthesis at codon 492 (p.(S492*)) in 
exon 14 and lead to nonsense mediated decay (Mutation Taster; probability = 1). It was 
possible to investigate segregation of LoF variants in two of these families (F4118 and 314) 
given the availability of DNA from other affected and unaffected relatives. In both cases 
variants segregated with NSCL/P in accordance with an autosomal dominant pattern with 
incomplete penetrance (Figure 1).  
A higher proportion of ARHGAP29 rare variants were found in NSCL/P probands as 
compared to controls (Supplementary Table 1) with a borderline level of significance (SKAT: 
P=0.06; Fisher´s exact: P=0.08; patients: 11/188, 5.85%; controls: 37/1210, 3.06%). Splitting 
the analysis by variant type, no significant difference in the distribution of missense variants 
with pathogenic in silico predictions was observed between groups (SKAT: P=0.35; Fisher: 
P=0.51; patients: 1/188, 0.53%; controls: 4/1210, 0.33%). On the other hand, the number of 
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LoF variants was significantly higher in patients (SKAT: P=0.0005; Fisher´s test: P=0.001; 
patients: 4/188, 2.13%; controls: 1/1210, 0.08%). 
Based on our findings, we hypothesized that the LoF variants are most likely implicated with 
NSCL/P. All four patients with LoF variants in ARHGAP29 have cleft lip (bilateral or 
unilateral) and cleft palate (Figure 1). Phenotype expressivity among affected relatives ranged 
from a lip scar to a bilateral cleft lip/palate. Considering that NSCL/P segregates in an 
autosomal dominant model, penetrance in the four families was estimated as 0.595 (CI 95%: 
0.375-0.803).  
To investigate whether penetrance effects in our families could be explained by common 
variants, we next evaluated if the LoF variants in ARHGAP29 were present in trans or in cis 
with the at-risk alleles of loci rs560426 and rs4147811, at 1p22, which were shown to be 
associated with NSCL/P by GWAS. We observed that all the six affected genotyped 
individuals were homozygous for at least one of these SNVs while one of the two non-
penetrant individuals was also homozygous for one of these SNVs (Figure 1).  
To take this idea further, we also tested if the at-risk allele of rs642961 24, located in the IRF6 
regulatory region, could influence the penetrance in individuals with ARHGAP29 LoF 
variants. This locus was also selected as it was previously suggested to be within the same 
pathway as ARHGAP29 11,25. We observed that four of the nine individuals genotyped for 
rs642961 harbored the at-risk allele A, two were affected (Figure 1, Family 314 individual II-
4 and Family F4118 individual II-2), while the two other individuals were non-penetrant 
mutation carriers (Figure 1, Family 314 individual II-2 and Family F4118 individual I-1). 
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These results suggest therefore that this SNP is unlikely to have a strong epistatic interaction 
with ARHGAP29. 
  
DISCUSSION 
Exome and genome analyses have been contributing exponentially to the description of novel 
rare variants in several healthy and disease populations, particularly in those of European 
ancestry. Consequently, one of the current challenges is to distinguish variants leading to 
phenotypic variability from those that do not, particularly those in the heterozygous state. 
These difficulties are illustrated by the finding that healthy human genomes harbor about 100-
250 LoF variants per individual 26. Studies of the distribution of rare variants in different 
populations with the phenotypes of interest are a possible approach to validate pathogenic 
variants. 
In the present study, ARHGAP29 mutation screening revealed five unique, rare heterozygous 
variants (one non-frameshift deletion and four LoF) and five already described rare missense 
variants in 188 NSCL/P families. In silico predictions of protein damage, segregation analysis 
and aggregation tests indicated that only the LoF variants, but not missense variants, in 
ARHGAP29 represent a major genetic risk factor for NSCL/P in our cohort. Indeed, according 
to ExAC database, while ARHGAP29 tolerates missense variants (ExAC Z-score: -0.27), it 
does not seem to tolerate LoF variants (ExAC Probability of LoF Intolerance: 1.00) 17. 
Structural variants involving ARHGAP29 are uncommon in the Database of Genomic 
Variants 27 while four of the five deletions in the Decipher database 28 involving ARHGAP29 
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are described with facial anomalies, including cleft palate. Further, down-regulation of 
ARHGAP29 by genetic and epigenetic changes in both alleles have also been shown to be 
important in the phenotypic determination of mantle cell lymphomas 29,30. Therefore, while 
there are evidence that LoF variants in ARHGAP29 contribute to the NSCL/P phenotype, 
missense variants should be functionally tested before their definition as pathogenic.  
The prevalence of rare LoF variants in our sample (2.1%) was higher than those observed in 
other NSCL/P large studies (0.2% - 0.5%) 11,12. Possibly, these differences reflect the familial 
enrichment of multiplex families over population-dependent factors in our cohort. 
Interestingly, an enrichment of CDH1 variants among familial cases (15%) were also 
observed in a previous study of our group 31. 
There is no evidence of a mutational hotspot within ARGHAP29 (Figure 2), although the 
modest number of known LoF variants may obscure such a finding. In our families, these 
variants are associated with a broad spectrum of inter and intrafamilial clinical variability, as 
reported by others 11–14 (Supplementary Table 2).  
In all four families with LoF ARHGAP29 variants, NSCL/P segregated according to an 
autosomal dominant inheritance model with incomplete penetrance (59%). We hypothesised 
that the NSCL/P penetrance in individuals with the LoF variants in ARHGAP29 could be 
modified by the presence of at-risk alleles identified by GWAS. Even though our data is 
based on a small sample, these preliminary results suggest that the SNVs at 1p22 or rs642961 
at IRF6 do not significantly contribute to the penetrance and do not support an interaction 
between ARHGAP29 and IRF6.  
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In summary, this study expands the mutational repertoire implicating ARHGAP29 with 
NSCL/P and provides evidence that heterozygous LoF variants in this gene confer a moderate 
risk to the disease and may be an important genetic factor at 1p22 driving the phenotype. In 
addition, given the incomplete penetrance observed, additional mechanisms may be required 
to trigger the phenotype. The study of multiplex families has proved to be an effective 
strategy to identify rare variants with moderate to high effect on NSCL/P since genetic factors 
that contribute to the etiology of the disease are likely to be more prevalent in this group of 
patients. Likewise, considering the relatively high proportion of families positive for LoF in 
ARHGAP29 (~2%), sequencing of this gene might be taken into consideration in genetic 
counseling of familial cases. 
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TITLES AND LEGENDS TO FIGURES  
 
Figure 1: Pedigrees of the NSCL/P families showing genotypes for ARHGAP29 LoF variants, 
1p22 SNVs (rs560426, rs4147811) and IRF6 SNV (rs642961). At-risk alleles are given in 
bold; the black and gray line indicate the recombination point; unavailable genotypes are 
indicated with “?”. 
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Figure 2: Scheme of the ARHGAP29 protein showing the distribution of rare germ-line LoF 
variants observed in NSCL/P patients. Variants described in our study are on top of the image 
and the variants described in the literature are below.  
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Supplementary Table 2: ATHGAP29 LOF variants in the literature 
